Changes in disease activity during pregnancy and the peri-partum period have long been recognized features of systemic autoimmune disease. Moreover, as certain autoimmune diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), frequently affect women of childbearing age, there is the potential for the disease to affect pregnancy outcomes. However, despite the frequency […]
Hematologic malignancies, particularly lymphomas, are more prevalent in RA patients. Case reports have suggested an association between RA therapeutics and the development of lymphoma, although it has been problematic using conventional epidemiologic methods to disassociate the potential for the RA disease process, presumably mediated through chronic systemic inflammation, to contribute to this risk. These concerns have limited the use of RA therapies in some patients.
Vitamin D plays an important role in bone metabolism and may also have immunomodulatory effects. Specifically, it has been shown in animals that vitamin D can suppress the effects of autoimmunity. Although we do not know whether a similar effect would be found in humans, no studies have assessed the association between Vitamin D and […]
Approximately one-third to half of patients with established RA will experience deterioration in symptom control in the year following discontinuation of disease-modifying anti-rheumatic drugs (DMARDs). Particularly for older DMARDS, such as parenteral gold and anti-malarials, reinstitution has been suggested to be less effective in controlling RA disease activity. Though this phenomenon is not as well […]